Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 3Thoracic 2Breast 2Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 6Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 18Nivolumab 6Radiotherapy 5Paclitaxel 5Trastuzumab 4Specimen Handling 4Ipilimumab 4tisotumab vedotin 3temsirolimus 3olaparib 3lenvatinib 3X-Rays 3Taxes 3Surveys and Questionnaires 3Early Intervention, Educational 3Cyclophosphamide 3Carboplatin 3Biopsy 3spartalizumab 2sargramostim 2rucaparib 2palbociclib 2fludarabine 2epacadostat 2enzalutamide 2durvalumab 2cabozantinib 2atezolizumab 2aflibercept 2Vinorelbine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × AZD5305 × Genitourinary × Clear all
NCT04644068 2026-02-19

PETRA

AstraZeneca

Phase 1/2 Active not recruiting
702 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡